Showing 7291-7300 of 9550 results for "".
- Promius Receives FDA Approval for Sernivo Spray for Psoriasishttps://practicaldermatology.com/news/promius-receives-fda-approval-for-sernivo-spray-for-psoriasis/2458715/Dr. Reddy’s US subsidiary Promius Pharma received FDA approval for Sernivo (betamethasone dipropionate) Spray 0.05%. Sernivo Spray, a prescription topical steroid, is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older. The commercial launch
- Novan Announces Robert A. Ingram as Chairmanhttps://practicaldermatology.com/news/novan-announces-robert-a-ingram-as-chairman/2458716/Novan, Inc. named Robert A. Ingram as Chairman of the Board of Directors of Novan. In addition, Robert Keegan has been appointed to the Board of Directors. The company also announced that it received $32.8 million of net proceeds in a private Mezzanine B financing in December 2015 from it
- ASDS: Cosmetic Treatments Can Correct Facial Deformities Toohttps://practicaldermatology.com/news/asds-cosmetic-treatments-can-correct-facial-deformities-too/2458714/Soft-tissue fillers, neurotoxins and lasers can be used to correct facial deformities caused by a variety of medical conditions, according to information presented at the 2015 American Society for Dermatologic Surgery meeting. During the session, Wa
- Dr. Andrew Krakowski Now CMO at DermOnehttps://practicaldermatology.com/news/andrew-krakowski-now-cmo-at-dermone/2458729/Andrew C. Krakowski, MD has joined DermOne, a network of comprehensive dermatology practices, as Chief Medical Officer. “The need for dermatology services has accelerated in recent years, due to an aging population, a growing demand for surgical and cosmetic procedures and a raised
- Valeant: FDA Accepts BLA for Brodalumabhttps://practicaldermatology.com/news/valeant-fda-accepts-bla-for-brodalumab/2458726/The FDA has accepted for review the Biologics License Application (BLA) submitted by AstraZeneca in partnership with Valeant, for brodalumab injection, 210mg, a monoclonal antibody that targets the IL-17 receptor, in development for patients with moderate-to-severe plaque psoriasis. The FDA has a
- Vyome Biosciences: FDA Has Accepted IND for Investigational Acne Therapyhttps://practicaldermatology.com/news/vyome-biosciences-fda-has-accepted-ind-for-investigational-acne-therapy/2458728/The FDA has accepted from Vyome Biosciences an Investigational New Drug (IND) Application for the initiation of clinical studies for its lead program VB 1953, a topical therapeutic candidate for the treatment of moderate-to-severe acne. Vyome plans to start the Phase I clinical trials very soon.<
- BioPharmX Corporation Appoints Craig A. Barbarosh to its Board of Directorshttps://practicaldermatology.com/news/biopharmx-corporation-appoints-craig-a-barbarosh-to-its-board-of-directors/2458734/BioPharmX Corporation appointed Craig A. Barbarosh to its board of directors. He will serve as an independent board member on the audit and compensation committees and will chair the nominating and corporate governance committee. Mr. Barbarosh is a member of the board of directors o
- New Web Tool May Curb Indoor Tanning Use Among Coedshttps://practicaldermatology.com/news/new-web-tool-may-curb-indoor-tanning-use-among-coeds/2458737/A web-based intervention that taps into indoor tanning users’ perceptions about the value of tanning may help curb tanning bed use among young females, suggests research out of Rutgers Cancer Institute of New Jersey in New Brunswick. Research has shown that some indoor tanners do so
- Study: MD Complete Holds Its Own Against Two Rx Skincare Regimenshttps://practicaldermatology.com/news/md-complete-holds-own-against-two-rx-skincare-regimens/2458736/A new split-face study suggests that a mass marketed skin care system can hold its own against two prescription skin care regimens when it comes to improving photoaged skin. The new findings, which compared MD Complete with two professi
- FDA Approves Two New indications for Cosentyxhttps://practicaldermatology.com/news/fda-approves-tow-new-indications-for-cosentyx/2458745/The FDA has approved Cosentyx® (secukinumab, Novartis) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA). AS and PsA are both life-long, painful and debilitating inflammatory diseases tha